Laurus Labs Share Price Jumps 5.35% to Record High of Rs 2,381.90 on 30 October 2026 as Laurus Labs Q2 Results Show Profit Up 126% and Rs 1 Laurus Labs Dividend Declared: Should You Buy?

The Laurus Labs share price hit a record high of Rs 2,381.90 on 30 October 2026 as Laurus Labs Q2 results showed profit up 126% and a Rs 1 Laurus Labs dividend was declared, record date 6 November. The stock was up 5.35% at Rs 2,364 by early afternoon on the NSE. Laurus Labs has now more than doubled in a year, Nuvama sees a target of Rs 2,520 while the analyst consensus sits near Rs 1,712, and the question for investors is whether the Laurus Labs share price rally has further to run or whether the stock has run ahead of its earnings.

This article covers the Laurus Labs Q2 results in detail, the Laurus Labs dividend record date and payment timeline, the Laurus Labs dividend yield, why the Laurus Labs share price is at a record, what brokerages are saying on the target price, and the risks to weigh before buying at these levels.

Click Here – Get Free Investment Predictions

Laurus Labs Share Price Today: Record High on 30 October 2026

The Laurus Labs share price opened at Rs 2,246.60 on the NSE the morning after the Laurus Labs Q2 results, dipped to Rs 2,206.10 in early trade, and then surged to a record high of Rs 2,381.90 before settling at Rs 2,364, up Rs 120 or 5.35% from the previous close of Rs 2,244. Volume on the NSE stood at 58.31 lakh shares by 1:07 PM, well above a normal session, which shows the Laurus Labs share price move after the Laurus Labs Q2 results is backed by broad participation rather than a thin squeeze. On the BSE the stock was at Rs 2,364.65, up 5.33%.

Metric	Value (30 October 2026)
NSE symbol	LAURUSLABS
Current market price	Rs 2,364 (up 5.35%)
Intraday high (record high)	Rs 2,381.90
Intraday low	Rs 2,206.10
Previous close	Rs 2,244
52-week low	Rs 917.95
Gain from 52-week low	About 157%
Market capitalisation	Rs 1,21,300 crore
P/E ratio (TTM)	111.25
Industry P/E	37.65
P/B ratio	22.89
Debt to equity	0.48
Laurus Labs dividend (interim)	Rs 1 per share, record date 6 November 2026

Source: NSE, BSE and company filings. Prices are as of 1:07 PM IST on 30 October 2026.

Laurus Labs Q2 Results 2026: Net Profit Up 126%, Revenue Up 33%

The Laurus Labs Q2 results for the quarter ended 30 September 2026 showed consolidated net profit attributable to equity holders of Rs 441.48 crore, up 126% from Rs 195 crore in Q2 FY26. Revenue from operations in the Laurus Labs Q2 results rose 33% to Rs 2,206.37 crore from Rs 1,653.47 crore a year earlier. EBITDA in the Laurus Labs Q2 results grew 78% to Rs 762 crore, and the EBITDA margin expanded by about 850 basis points to 34.5%, which is the single biggest reason the Laurus Labs share price reacted so strongly to the Laurus Labs Q2 results.

Laurus Labs Q2 results metric	Q2 FY27	Q2 FY26	YoY change
Revenue from operations	Rs 2,206 crore	Rs 1,653 crore	Up 33%
EBITDA	Rs 762 crore	Rs 429 crore	Up 78%
EBITDA margin	34.5%	About 26%	Up about 850 bps
Net profit	Rs 441 crore	Rs 195 crore	Up 126%
CDMO revenue	Rs 904 crore	Rs 518 crore	Up 75%
Affordable medicines revenue	Rs 1,302 crore	About Rs 1,132 crore	Up 15%
R&D spend	Rs 65 crore (2.9% of revenue)

Source: Company press release and exchange filing dated 29 October 2026. For the first half of FY27, net profit rose 126% to Rs 809 crore from Rs 358 crore in H1 FY26, so the Laurus Labs Q2 results were not a one-off.

CDMO Is Now the Growth Engine

The CDMO division, the biggest driver of the Laurus Labs share price this year, delivered revenue of Rs 904 crore in Q2 FY27, up 75% year on year, driven by late-stage programmes and commercial API supplies to multiple global innovator partners. That makes CDMO about 41% of the revenue in the Laurus Labs Q2 results, up from roughly 31% a year ago. Management said on the Laurus Labs Q2 results call that the margin improvement came from both lower R&D intensity and operating leverage on the extra Rs 200 crore of revenue. The affordable medicines segment, which includes the antiretroviral franchise, grew 15% to Rs 1,302 crore on stable pricing and a larger order book. The only weak spot in the Laurus Labs Q2 results was Laurus Bio, where sales fell to Rs 29 crore due to campaign phasing, with commercial supplies from the new LB4 facility expected only in Q1 FY28.

Peptide Capacity and Two Acquisitions

Alongside the Laurus Labs Q2 results and the Laurus Labs dividend, the company said it has commissioned a commercial-scale peptide manufacturing block with over 16,000 litres of solid phase peptide synthesis capacity, and it is expanding that capacity further to meet demand from GLP-1 and other peptide programmes. The board also approved majority stakes in two businesses: Galenvs Sciences, an oligonucleotide development and manufacturing company, for USD 3.75 million including a USD 2.75 million primary infusion, and SANC Resins, a maker of peptide resins. Both deals announced with the Laurus Labs Q2 results and the Laurus Labs dividend are small in rupee terms but strategic, because they bring new modality capabilities in house and secure supply for the CDMO pipeline.

Check the Univest Screener for live Laurus Labs stock data

Laurus Labs Dividend 2026: Rs 1 Interim Dividend, Record Date 6 November

The Laurus Labs dividend announced on 29 October 2026, which also lifted the Laurus Labs share price, is an interim dividend of Rs 1 per equity share of face value Rs 2, which is 50% of face value, and it is the first Laurus Labs dividend of FY27. The Laurus Labs dividend record date is Thursday, 6 November 2026, so investors need to hold the shares by the end of 5 November 2026 to be eligible, keeping the T+1 settlement cycle in mind. The company expects to credit the Laurus Labs dividend on or after 19 November 2026. Investors who buy the stock on or after 6 November will not receive this Laurus Labs dividend.

Laurus Labs dividend detail	Value
Type	Laurus Labs dividend, interim, for FY 2026-27
Amount	Rs 1 per share (50% of Rs 2 face value)
Record date	6 November 2026
Payment date	On or after 19 November 2026
Laurus Labs dividend yield at Rs 2,364	About 0.04% for this payout

At a Laurus Labs share price of Rs 2,364, a Rs 1 Laurus Labs dividend is a yield of only about 0.04%, so nobody is buying the stock for income. The Laurus Labs dividend matters more as a signal, because the company is choosing to return a small amount of cash while it keeps investing in capacity: the board is comfortable returning cash even though cash and cash equivalents fell to Rs 24.45 crore at the end of September from Rs 112.66 crore in March 2026, because operating cash flow from the CDMO ramp is improving.

Why Is Laurus Labs Share Price at a Record High?

The Laurus Labs share price is at a record high because the Laurus Labs Q2 results beat brokerage estimates on every line, the EBITDA margin of 34.5% reached a level management had guided for only over the medium term, and the CDMO pipeline now has visible commercial supplies rather than only development revenue. The Laurus Labs share price had already rallied 4% on each of the two sessions before the Laurus Labs Q2 results, hitting a new high on 27 October, as Nuvama initiated coverage with a Buy and the market positioned for a strong quarter. Add the Rs 1 Laurus Labs dividend and the two acquisitions, and the result day became a catalyst for a fresh leg up in the Laurus Labs share price.

Laurus Labs Share Price Target: What Brokerages Say

Brokerage views on the Laurus Labs share price after the Laurus Labs Q2 results are split, and the split is wide. Nuvama Institutional Equities initiated coverage on the Laurus Labs share price in October 2026 with a Buy rating and a target price of Rs 2,520, arguing that the new peptide facility can add Rs 1,000 crore to Rs 1,600 crore in revenue at a 35% margin and lift the group EBITDA margin profile to near 35%. Motilal Oswal had a Buy with a target price of Rs 1,980 after the Q1 FY27 results in July 2026, a level the stock has already crossed, and the brokerage has consistently raised its estimates after each beat, so a fresh upgrade after the Laurus Labs Q2 results is possible. The wider consensus from about 15 analysts is a Hold with an average target price near Rs 1,712, which is roughly 28% below the current price.

Brokerage	Rating	Laurus Labs share price target	Note
Nuvama Institutional Equities	Buy	Rs 2,520	Initiated October 2026, peptide and CDMO upside
Motilal Oswal	Buy	Rs 1,980	Post Q1 FY27, target already crossed
Analyst consensus (about 15 analysts)	Hold	Rs 1,712	Average target below current price

The gap between Nuvama's Rs 2,520 and the consensus Rs 1,712 captures the Laurus Labs share price debate. The bulls say the Laurus Labs Q2 results show earnings compounding at over 100% and the CDMO mix shift deserves a premium multiple. The cautious camp points out that at 111 times trailing earnings versus an industry P/E of 37.65, the Laurus Labs share price already discounts two to three years of strong growth.

Download the Univest iOS App or Univest Android App to track the Laurus Labs share price live and get daily stock research.

Should You Buy Laurus Labs Stock After Q2 Results?

Buying Laurus Labs at a record high is a bet on the CDMO and peptide story continuing to deliver 70% plus growth for several more quarters, because the Laurus Labs share price valuation leaves little room for a miss when the Q3 numbers follow the Laurus Labs Q2 results in January. The earnings support for the Laurus Labs share price is real: net profit more than doubled, the EBITDA margin is at 34.5%, debt to equity is a comfortable 0.48, and FIIs hold 30.8% of the company against 27.5% with promoters. The risks are equally real. A trailing P/E of 111 times, even after the strong Laurus Labs Q2 results, is nearly three times the industry average, Laurus Bio is still not contributing, and any slowdown in late-stage CDMO programmes or pricing pressure in antiretrovirals would hit a stock priced for perfection.

Existing investors have a strong case to stay invested in Laurus Labs stock with a trailing stop loss, and to hold through the Laurus Labs dividend record date on 6 November, since the trend and the earnings both point the same way. New investors may prefer to buy in tranches or wait for a pullback towards the Rs 2,200 to Rs 2,250 zone, where the Laurus Labs share price was trading before the Laurus Labs Q2 results, rather than chase the first day of a breakout. Consult a SEBI-registered financial advisor before taking a position.

Subscribe to Univest Pro for premium pharma stock research

Conclusion

The Laurus Labs share price at a record high of Rs 2,381.90 on 30 October 2026 is the market's verdict on a quarter in which net profit rose 126% to Rs 441 crore, the EBITDA margin expanded 850 basis points to 34.5% and CDMO revenue jumped 75% to Rs 904 crore. The Rs 1 Laurus Labs dividend with a 6 November record date and the two peptide and oligonucleotide acquisitions announced with the Laurus Labs Q2 results add to the growth narrative. With Nuvama at Rs 2,520 and consensus at Rs 1,712, the next move depends on whether the Q3 FY27 numbers keep the margin above 34% and whether the new peptide block starts generating revenue on schedule.

Frequently Asked Questions on Laurus Labs Share Price and Q2 Results

What is the Laurus Labs share price today, 30 October 2026?

Ans. The Laurus Labs share price is Rs 2,364 on the NSE as of 1:07 PM on 30 October 2026, up 5.35% from the previous close of Rs 2,244. The stock opened at Rs 2,246.60, fell to Rs 2,206.10 and then rallied to a record high of Rs 2,381.90 during the session. The Laurus Labs share price gain came a day after the Laurus Labs Q2 results, and the market capitalisation at this price is about Rs 1,21,300 crore, and the stock is about 157% above its 52-week low of Rs 917.95.

What were the Laurus Labs Q2 results for FY27?

Ans. Laurus Labs reported Q2 FY27 consolidated net profit of Rs 441.48 crore, up 126% from Rs 195 crore a year earlier, on revenue of Rs 2,206.37 crore, up 33% from Rs 1,653.47 crore. EBITDA rose 78% to Rs 762 crore and the EBITDA margin expanded by about 850 basis points to 34.5%. CDMO revenue grew 75% to Rs 904 crore, affordable medicines revenue grew 15% to Rs 1,302 crore, and first-half net profit rose 126% to Rs 809 crore. The board also approved a Laurus Labs dividend of Rs 1 per share alongside the Laurus Labs Q2 results.

What is the Laurus Labs dividend record date and amount?

Ans. The Laurus Labs dividend is an interim dividend of Rs 1 per equity share of Rs 2 face value, which is 50% of face value, declared by the board on 29 October 2026. The record date is 6 November 2026, so shareholders holding the stock on that date will be eligible, and the company expects to credit the dividend on or after 19 November 2026. At a Laurus Labs share price of Rs 2,364 the Laurus Labs dividend works out to a yield of about 0.04%.

Why did Laurus Labs share price hit a record high after Q2 results?

Ans. Laurus Labs share price hit a record high of Rs 2,381.90 on 30 October 2026 because the Laurus Labs Q2 results beat brokerage estimates on revenue, EBITDA and profit, with net profit more than doubling and the EBITDA margin reaching 34.5%. The 75% growth in CDMO revenue, a commissioned peptide manufacturing block, two acquisitions in oligonucleotides and peptide resins, and a Rs 1 Laurus Labs dividend added to the positive sentiment. The stock had also been rising ahead of results after Nuvama initiated coverage with a Buy rating.

What is the Laurus Labs share price target after Q2 FY27 results?

Ans. Nuvama Institutional Equities has a Buy rating on Laurus Labs after the Laurus Labs Q2 results with a target price of Rs 2,520, which implies about 7% upside from Rs 2,364, based on the peptide facility adding Rs 1,000 crore to Rs 1,600 crore in revenue at a 35% margin. Motilal Oswal had a Buy with a Rs 1,980 target after Q1 FY27, which the stock has already crossed. The consensus of about 15 analysts is a Hold with an average target near Rs 1,712, below the current price. These are brokerage estimates and not guaranteed outcomes.

Should I buy Laurus Labs shares after the Q2 results?

Ans. Buying Laurus Labs after the Laurus Labs Q2 results depends on your risk appetite, because the stock trades at a trailing P/E of about 111 times against an industry P/E of 37.65 even though earnings are growing above 100%. Existing investors have a case to stay invested with a trailing stop loss given the earnings momentum and the 34.5% EBITDA margin. New investors may prefer to buy in tranches or wait for a Laurus Labs share price dip towards Rs 2,200 to Rs 2,250 rather than chase the record high, keeping in mind that the Laurus Labs dividend record date is 6 November 2026. This is not investment advice, so consult a SEBI-registered financial advisor before you decide.

What acquisitions did Laurus Labs announce with its Q2 results?

Ans. Along with the Laurus Labs Q2 results and the Laurus Labs dividend, the company announced majority stake acquisitions in Galenvs Sciences, an oligonucleotide development and manufacturing company, for USD 3.75 million including a USD 2.75 million primary infusion, and in SANC Resins, a maker of peptide resins. Both deals are aimed at strengthening the company's CDMO offering in new modalities such as oligonucleotides and peptides, and at securing raw material supply for its expanding peptide manufacturing capacity of over 16,000 litres of solid phase synthesis.

What are the main risks for Laurus Labs stock at the current price?

Ans. The main risks for Laurus Labs stock after the Laurus Labs Q2 results are its valuation at about 111 times trailing earnings and 22.9 times book value, a dependence on late-stage CDMO programmes that can be lumpy from quarter to quarter, and the Laurus Bio division where sales fell to Rs 29 crore in Q2 with commercial supplies from the LB4 plant expected only in Q1 FY28. Pricing pressure in antiretroviral medicines, a reduction in cash and cash equivalents to Rs 24.45 crore in September 2026, and the stock's 157% rally from its 52-week low, which raises the chance of profit booking, are other factors that could weigh on the Laurus Labs share price.